M&A / Deals Lilly to acquire CrossBridge Bio for up to $300m Pharmaceutical TechnologyEli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.M&A / DealsRead full story pharminent April 15, 2026 Pharmaceutical Technology Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash. M&A / DealsRead full story Post navigation Previous: Lilly to acquire CrossBridge Bio for up to $300mNext: FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
